Monitor the voting results for any unexpected opposition to director elections or auditor ratification, which could indicate shareholder concerns. Otherwise, this is a standard annual meeting with no immediate financial implications.
CRBU drugs
CRBU drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $2.13entry
- T+1 · 7mo ago −2.35%α −1.86% · $2.08
- T+5 · 7mo ago −10.33%α −10.73% · $1.91
- T+20 · 6mo ago +1.41%α −3.55% · $2.16
- T+60 · 4mo ago −22.07%α −26.84% · $1.66
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Caribou Biosciences is holding its 2026 annual meeting where shareholders will vote on electing three Class II directors, ratifying Deloitte & Touche LLP as auditors, approving an amendment to exculpate officers from certain fiduciary duties, and adjourning the meeting if needed. This is a routine annual shareholder meeting with no material financial impact.
Key Financial Metrics
Key Facts
- Election of three Class II directors: Andrew Guggenhime, David Johnson, and Nancy Whiting
- Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026
- Approval of amendment to provide for exculpation of officers from certain breaches of fiduciary duty
- Approval of adjourning the 2026 Annual Meeting if necessary for further solicitation of proxies
Financial Impact
No direct financial impact from these proposals
Risk Factors
- Potential shareholder opposition to officer exculpation amendment
- Unexpected vote against auditor ratification could signal governance concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001619856-26-000023 |
| Document: 0001619856-26-000023-index-headers.html | 0001619856-26-000023 |
| Document: 0001619856-26-000023-index.html | 0001619856-26-000023 |
| Document: 0001619856-26-000023.txt | 0001619856-26-000023 |
Track record
13 reports on CRBU
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Viewing Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers